Laval, Canada-based Valeant Pharmaceuticals' board of directors elected Richard DeSchutter director.
Here's what you should know.
1. The latest appointment to the board increases its size to 13 members; 12 of which are independent.
2. Mr. DeSchutter was the former chairman and CEO of DuPont Pharmaceuticals before Bristol-Myers Squibb acquired the company. He recently served as the director of Ft. Lauderdale, Fla.-based AuVen Therapeutics.
3. Valeant CEO Joseph Papa lauded the hire saying "His track record of pharmaceutical company leadership combined with his operational and financial advisory experience make him an ideal addition to our board. We look forward to is strategic insights as we reposition and reinvigorate the company in 2017."
More articles on gastroenterology/endoscopy:
Diet therapy may improve clinical, microbial symptoms in IBD patients: 4 study insights
Boston Scientific, CapsoVision & more — 3 GI company key notes
GI leader to know: Dr. J. Scott Buckley of Indy Gastro